AnaptysBio Enters Material Definitive Agreement

TL;DR

ANAB signed a big deal on Jan 31st, filing today.

AI Summary

On January 31, 2025, AnaptysBio, Inc. entered into a material definitive agreement. The company, incorporated in Delaware with its principal executive offices in San Diego, CA, filed this 8-K report on February 3, 2025. The filing details an event that occurred as of January 31, 2025.

Why It Matters

This filing indicates a significant new contract or partnership for AnaptysBio, which could impact its future operations and financial performance.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce new risks and obligations for a company, but the specific nature of the agreement is not detailed in this summary.

Key Numbers

• 001-37985 — SEC File Number (Identifies the company's filings with the SEC)
• 20-3828755 — IRS Employer Identification No. (Company's tax identification number)

Key Players & Entities

• ANAPTYSBIO, INC (company) — Registrant
• January 31, 2025 (date) — Date of earliest event reported
• February 3, 2025 (date) — Filing date
• Delaware (jurisdiction) — State of Incorporation
• San Diego, CA (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share ANAB The Nasdaq Stock Marke
• $10 million — ptys will receive an upfront payment of $10 million and a $5 million payment for existing d
• $5 million — an upfront payment of $10 million and a $5 million payment for existing drug supply. Anapt
• $35 million — aptys is also eligible to receive up to $35 million for future regulatory approval and sale

Filing Documents

• anab-20250131.htm (8-K) — 27KB
• anab-pressrelease2025x01.htm (EX-99.1) — 14KB
• anab-pressrelease2025x01001.jpg (GRAPHIC) — 244KB
• anab-pressrelease2025x01002.jpg (GRAPHIC) — 284KB
• anab-pressrelease2025x01003.jpg (GRAPHIC) — 282KB
• anab-pressrelease2025x01004.jpg (GRAPHIC) — 171KB
• 0001370053-25-000002.txt ( ) — 1564KB
• anab-20250131.xsd (EX-101.SCH) — 2KB
• anab-20250131_def.xml (EX-101.DEF) — 9KB
• anab-20250131_lab.xml (EX-101.LAB) — 29KB
• anab-20250131_pre.xml (EX-101.PRE) — 20KB
• anab-20250131_htm.xml (XML) — 3KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On January 31, 2025, AnaptysBio, Inc. ( " Anaptys " ) entered into an Exclusive License Agreement (the " License Agreement " ) with Vanda Pharmaceuticals Inc. ( " Vanda " ) pursuant to which Anaptys granted to Vanda an exclusive, global license for the development and commercialization of imsidolimab (IL-36R antagonist mAb), which has completed two registration-enabling global Phase 3 trials, GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of imsidolimab in patients with Generalized Pustular Psoriasis (GPP). Pursuant to the terms of the License Agreement, Anaptys will receive an upfront payment of $10 million and a $5 million payment for existing drug supply. Anaptys is also eligible to receive up to $35 million for future regulatory approval and sales milestones in addition to a 10% royalty on net sales. The License Agreement includes various representations, warranties, covenants, indemnities, and other customary provisions and contains customary provisions for termination (i) by Vanda following the three-year anniversary of the effective date of the License Agreement upon at least 12 months' prior written notice to Anaptys or (ii) by either party in the event of breach of the License Agreement (subject to cure), subject, in each case, to certain reversion rights, or upon the other party's bankruptcy. The foregoing summary of the License Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the License Agreement. A copy of the License Agreement will be filed as an exhibit to AnaptysBio's Quarterly Report on Form 10Q for the quarter ended March 31, 2025.

01. Regulation FD

Item 7.01. Regulation FD. On February 3, 2025, AnaptysBio issued a press release announcing the entry into the License Agreement with Vanda, a copy of which is attached hereto as Exhibit 99.1. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing. Exhibit Number Exhibit Title or Description 99.1 Press release issued by AnaptysBio, Inc. regarding the Vanda Exclusive License Agreement, dated January 31, 2025. 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. AnaptysBio, Inc. Date: February 3, 2025 By: /s/ Eric Loumeau Name: Eric Loumeau Title: Chief Legal Officer

View Full Filing

View this 8-K filing on SEC EDGAR